Physician profile
Todd A Mahr
NPI 1659374411
$717,885.26
in general payments reported to CMS, 2019-2025
25 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214K · 2020: $54K · 2021: $88K · 2022: $89K · 2023: $95K · 2024: $91K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140K · Consulting Fee: $90K · Travel and Lodging: $32K · Food and Beverage: $5,872 · Honoraria: $3,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,442.58 |
| Consulting Fee | $90,262.00 |
| Travel and Lodging | $32,254.81 |
| Food and Beverage | $5,871.97 |
| Honoraria | $3,450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $311,148.26 | 2019-2025 | Dupixent |
| Genzyme Corporation | $189,044.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $103,008.61 | 2019-2025 | Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $39,357.06 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Kaleo, INC. | $30,916.93 | 2019-2025 | Auvi-Q |
| Aimmune Therapeutics, INC. | $13,350.48 | 2022-2023 | |
| Optinose US, INC. | $9,600.74 | 2019-2020 | |
| Alk-Abello, INC | $8,321.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $6,797.26 | 2023-2024 | |
| Perrigo Company Plc | $3,000.00 | 2021 | |
| Amgen INC. | $1,486.00 | 2022-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $782.00 | 2019 | |
| Gilead Sciences, INC. | $296.54 | 2019-2021 | |
| Chiesi USA, INC. | $200.96 | 2019-2020 | |
| Circassia INC. | $163.35 | 2022-2023 | Niox |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $130.92 | 2019 | |
| Allergan, INC. | $90.00 | 2019 | |
| Blueprint Medicines Corporation | $72.84 | 2023 | |
| Pharming Healthcare, INC. | $34.30 | 2024 | Ruconest |
| Vivus LLC | $27.49 | 2021-2022 | |
| Phadia US INC. | $24.50 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.11 | 2022 | |
| Genentech USA, INC. | $11.78 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Mahr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.